Lenders, Malte ORCID: 0000-0001-8409-2886, Nordbeck, Peter ORCID: 0000-0002-2560-4068, Kurschat, Christine, Eveslage, Maria ORCID: 0000-0002-8802-1134, Karabul, Nesrin, Kaufeld, Jessica, Hennermann, Julia B., Patten, Monica, Cybulla, Markus, Muentze, Jonas, Ueceyler, Nurcan, Liu, Dan, Das, Anibh M., Sommer, Claudia, Pogoda, Christian, Reiermann, Stefanie, Duning, Thomas, Gaedeke, Jens, Stumpfe, Katharina, Blaschke, Daniela, Brand, Stefan-Martin, Mann, W. Alexander, Kampmann, Christoph, Muschol, Nicole, Canaan-Kuhl, Sima and Brand, Eva . Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). EUR. HEART J.-CARDIOVASC. PHARMACOTHER.. OXFORD: OXFORD UNIV PRESS. ISSN 2055-6845

Full text not available from this repository.

Abstract

Aims Fabry disease (FD) is an X-linked lysosomal storage disorder caused by a deficiency of the lysosomal enzyme alpha-galactosidase A (GLA/AGAL), resulting in the lysosomal accumulation of globotriaosylceramide (Gb(3)). Patients with amenable GLA mutations can be treated with migalastat, an oral pharmacological chaperone increasing endogenous AGAL activity. In this prospective observational multicentre study, safety as well as cardiovascular, renal, and patient-reported outcomes and disease biomarkers were assessed after 12 and 24 months of migalastat treatment under 'real-world' conditions. Methods and results A total of 54 patients (26 females) (33 of these [61.1%] pre-treated with enzyme replacement therapy) with amenable mutations were analysed. Treatment was generally safe and well tolerated. A total of 153 events per 1000 patient-years were detected. Overall left ventricular mass index decreased after 24 months (all: -7.5 +/- 17.4 g/m(2), P = 0.0118; females: -4.6 +/- 9.1 g/m(2), P = 0.0554; males: -9.9 +/- 22.2 g/m(2), P = 0.0699). After 24 months, females and males presented with a moderate yearly loss of estimated glomerular filtration rate (-2.6 and -4.4 mL/min/1.73 m(2) per year; P = 0.0317 and P = 0.0028, respectively). FD-specific manifestations/symptoms remained stable (all P > 0.05). A total of 76.9% of females and 50% of males suffered from pain, which has not improved under treatment. FD-specific disease scores (Disease Severity Scoring System and Mainz Severity Score Index) remained stable during treatment. AGAL activities and plasma lyso-Gb(3) values remained stable, although some male patients presented with increasing lyso-Gb(3) levels over time. Conclusions Treatment with migalastat was generally safe and resulted in most patients in an amelioration of left ventricular mass. However, due to the heterogeneity of FD phenotypes, it is advisable that the treating physician monitors the clinical response regularly.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Lenders, MalteUNSPECIFIEDorcid.org/0000-0001-8409-2886UNSPECIFIED
Nordbeck, PeterUNSPECIFIEDorcid.org/0000-0002-2560-4068UNSPECIFIED
Kurschat, ChristineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Eveslage, MariaUNSPECIFIEDorcid.org/0000-0002-8802-1134UNSPECIFIED
Karabul, NesrinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kaufeld, JessicaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hennermann, Julia B.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Patten, MonicaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Cybulla, MarkusUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Muentze, JonasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Ueceyler, NurcanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Liu, DanUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Das, Anibh M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sommer, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pogoda, ChristianUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Reiermann, StefanieUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Duning, ThomasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gaedeke, JensUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Stumpfe, KatharinaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Blaschke, DanielaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brand, Stefan-MartinUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mann, W. AlexanderUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kampmann, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Muschol, NicoleUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Canaan-Kuhl, SimaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Brand, EvaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-600880
DOI: 10.1093/ehjcvp/pvab025
Journal or Publication Title: EUR. HEART J.-CARDIOVASC. PHARMACOTHER.
Publisher: OXFORD UNIV PRESS
Place of Publication: OXFORD
ISSN: 2055-6845
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
ENZYME REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE; NATURAL-HISTORY; RENAL-FUNCTION; EVENTS; REDUCTION; IMPACT; SAFETYMultiple languages
Cardiac & Cardiovascular Systems; Pharmacology & PharmacyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/60088

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item